Bone Marrow Transplantation News

NEW ORLEANS — Patients with newly diagnosed mantle cell lymphoma who received ibrutinib with a standard-of-care regimen had higher failure-free survival rates than those who received standard-of-care treatment alone.

NEW ORLEANS — Adults undergoing stem cell transplant who received a nonrestrictive diet had similar rates of infection, feeding outcomes and acute graft-versus-host disease as those on a low-microbial protective diet, according to a study.

Hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry, study results showed.

Maintenance therapy with eprenetapopt plus azacitidine after hematopoietic stem cell transplantation led to improved survival outcomes among patients with TP53-mutant acute myeloid leukemia or myelodysplastic syndrome, study results showed.

For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list.

Matthew Matasar, MD, MS, has been named chief of blood disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health.

Guidelines on revaccination after cell therapy are clear for some patients but lack evidence-based consensus for others, according to an expert in infectious disease who spoke at NCCN 2022 Annual Congress: Hematologic Malignancies.

Four individuals have been elected to American Society of Hematology’s executive committee.

The basic science discoveries to which Helen E. Heslop, MD, DSc (Hon), has contributed place her firmly on the Mount Rushmore of pioneers in the field of gene and cell therapy.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 10-13 in New Orleans.